Cover Image

Not for Sale



View/Hide Left Panel

Herpesvirus varicellae

Attenuated live virus

Recipients of bone narrow and organ transplants and persons under age 25 with leukemias and lymphomas

90

5–10% local; 35–40% mild rash; unpredictable number of probably mild H. zoster infections possible

SC

2

25

Freezing of lyophilized preparation until in distribution chain

Minor

 

 

Normal susceptibles, routine for children (booster for adults)

90% (duration unknown)

5–10% local; unpredictable number of probably mild H. zoster infections possible

SC

2 (1 for children plus boosters for adults)

25

Freezing of lyophilized preparation until in distribution chain

Minor

Influenza viruses A & B

Purified hemagglutinin/ neuraminidase proteins

High-risk population as currently defined (see Appendix K)

85% for correct match of vaccine and prevalent strain

Essentially none

SC

Primary+ booster annually

15

Nothing unusual

Not unusual

 

Attenuated live virus

High-risk population as currently defined (see Appendix K)

85% for correct match of vaccine and prevalent strain

Essentially none

Intranasal

1 (possibly 2)

10

Freezing

Minor

Neisseria gonorrhoeae

A small number of promising options need investigation to determine best approach

Adolescents and adults age 15 and over

85% for pelvic inflammatory disease; 70% for mucosal

None

Local and parenteral

3 + boosters

20

Nothing unusual

Not unusual

Parainfluenza viruses

Trivalent, subunit vaccine (must contain fusion protein)

Infants

80% (against severe disease in young children)

None

SC

2+boosters

15

Nothing unusual

Not unusual

Respiratory syncytial virus

Glycoprotein produced by recombinant DNA technology

Infants

80% (against severe disease in young children)

None

SC

2+booster

15

Nothing unusual

Not unusual

 

 

 

 

 

 

15

Nothing unusual

Not unusual

 

Attenuated live virus

Infants

80% (against severe disease in young children)

None

Intranasal

1 (possibly 2)

 

 

 

Rotavirus

Attenuated live bovine virus

Infants

90

Minimal

Oral

1–2

Less than 10

Nothing unusual

Not unusual

 

Attenuated live human or reassortment virus

Infants

90

Probably none

Oral plus parenteral

1–2

Less than 10

Nothing unusual

Not unusual

 

 

 

 

 

May need to com- bine oral and parenteral immunization for effective response

 

 

 

 

Streptococcus group B

Conjugated polysaccharide

Pregnant women for fetuses and neonates

80

5% local; safety trial difficult

IM

1

20–25

Freezing

Not unusual



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement